MTC DOX

Drug Profile

MTC DOX

Alternative Names: Doxorubicin - FeRx; Magnetic targeted carrier technology - doxorubicin; MTC-DOX

Latest Information Update: 24 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FeRx
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action Reactive oxygen species stimulants; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer

Highest Development Phases

  • Discontinued Liver cancer

Most Recent Events

  • 05 May 2004 Discontinued - Phase-II/III for Liver cancer in Asia (Intra-arterial)
  • 05 May 2004 Discontinued - Phase-II/III for Liver cancer in Europe (Intra-arterial)
  • 05 May 2004 Discontinued - Phase-II/III for Liver cancer in North America (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top